[go: up one dir, main page]

MX2017015294A - Administracion intrapulmonar de agonistas de polinucleotidos del receptor 9 tipo toll para el tratamiento contra el cancer de pulmon. - Google Patents

Administracion intrapulmonar de agonistas de polinucleotidos del receptor 9 tipo toll para el tratamiento contra el cancer de pulmon.

Info

Publication number
MX2017015294A
MX2017015294A MX2017015294A MX2017015294A MX2017015294A MX 2017015294 A MX2017015294 A MX 2017015294A MX 2017015294 A MX2017015294 A MX 2017015294A MX 2017015294 A MX2017015294 A MX 2017015294A MX 2017015294 A MX2017015294 A MX 2017015294A
Authority
MX
Mexico
Prior art keywords
receptor
agonists
intrapulmonary administration
treating cancer
lung
Prior art date
Application number
MX2017015294A
Other languages
English (en)
Other versions
MX381587B (es
Inventor
L Coffman Robert
Guiducci Cristiana
Original Assignee
Dynavax Tech Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dynavax Tech Corp filed Critical Dynavax Tech Corp
Publication of MX2017015294A publication Critical patent/MX2017015294A/es
Publication of MX381587B publication Critical patent/MX381587B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente descripción se refiere a métodos para tratar el cáncer mediante la administración intrapulmonar de un agonista de polinucleótidos del receptor 9 tipo TolI. Los métodos de la presente descripción son adecuados para tratar el cáncer primario de pulmón, así como el cáncer metastásico en el pulmón y cánceres extrapulmonares del mismo. Además, la presente descripción proporciona agonistas de polinucleótidos del receptor 9 tipo Toll con perfiles inmunoestimuladores y de toxicidad adecuados para su administración intrapulmonar.
MX2017015294A 2015-05-29 2016-05-23 Agonistas de polinucleótidos del receptor 9 tipo toll y composiciones farmacéuticas de los mismos. MX381587B (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201562168449P 2015-05-29 2015-05-29
US201562168470P 2015-05-29 2015-05-29
US201562169321P 2015-06-01 2015-06-01
US201562169309P 2015-06-01 2015-06-01
US201662276767P 2016-01-08 2016-01-08
PCT/US2016/033817 WO2016196062A1 (en) 2015-05-29 2016-05-23 Intrapulmonary administration of polynucleotide toll-like receptor 9 agonists for treating cancer of the lung

Publications (2)

Publication Number Publication Date
MX2017015294A true MX2017015294A (es) 2018-02-19
MX381587B MX381587B (es) 2025-03-12

Family

ID=56098419

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017015294A MX381587B (es) 2015-05-29 2016-05-23 Agonistas de polinucleótidos del receptor 9 tipo toll y composiciones farmacéuticas de los mismos.

Country Status (14)

Country Link
US (3) US9993495B2 (es)
EP (2) EP3302502B1 (es)
JP (1) JP6792294B2 (es)
KR (1) KR102779525B1 (es)
CN (1) CN107708706A (es)
AU (1) AU2016270782B2 (es)
CA (1) CA2987237A1 (es)
DK (1) DK3302502T3 (es)
ES (2) ES2752063T3 (es)
HK (1) HK1251471A1 (es)
IL (1) IL255903B (es)
MX (1) MX381587B (es)
RU (1) RU2017145940A (es)
WO (1) WO2016196062A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8158768B2 (en) * 2002-12-23 2012-04-17 Dynavax Technologies Corporation Immunostimulatory sequence oligonucleotides and methods of using the same
EP4029508A1 (en) 2014-10-10 2022-07-20 Idera Pharmaceuticals, Inc. Treatment of cancer using tlr9 agonists and checkpoint inhibitors
CA2968531A1 (en) 2014-11-21 2016-05-26 Northwestern University The sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates
ES2752063T3 (es) * 2015-05-29 2020-04-02 Dynavax Tech Corp Administración intrapulmonar de agonistas polinucleotídicos del receptor de tipo toll 9 para el tratamiento del cáncer de pulmón
US11364304B2 (en) 2016-08-25 2022-06-21 Northwestern University Crosslinked micellar spherical nucleic acids
US10463686B2 (en) 2016-09-15 2019-11-05 Idera Pharmaceuticals, Inc. Immune modulation with TLR9 agonists for cancer treatment
US11433131B2 (en) 2017-05-11 2022-09-06 Northwestern University Adoptive cell therapy using spherical nucleic acids (SNAs)
WO2020081398A1 (en) * 2018-10-14 2020-04-23 Dynavax Technologies Corporation Combination including a cpg-c type oligonucleotide and a pd-1 antagonist for treating breast cancer
WO2020079185A1 (en) * 2018-10-18 2020-04-23 Deutsches Krebsforschungszentrum Dry pharmaceutical composition for inhalation
CN111321159B (zh) * 2018-12-14 2023-12-12 中天(上海)生物科技有限公司 用于免疫调节的嵌合核酸分子及其应用
WO2020128893A1 (en) * 2018-12-21 2020-06-25 Pfizer Inc. Combination treatments of cancer comprising a tlr agonist
EP3993834A1 (en) 2019-07-05 2022-05-11 Tambo, Inc. Trans-cyclooctene bioorthogonal agents and uses in cancer and immunotherapy
CN113122541A (zh) * 2019-12-31 2021-07-16 财团法人工业技术研究院 核酸药物复合体以及其用途
WO2022032191A1 (en) 2020-08-07 2022-02-10 Tambo, Inc. Trans-cyclooctene bioorthogonal agents and uses in cancer and immunotherapy
CN114099535B (zh) * 2020-12-10 2023-01-03 南京吉迈生物技术有限公司 Toll样受体9(TLR9)激动剂水凝胶免疫调节组合物
WO2022140661A1 (en) * 2020-12-23 2022-06-30 Cascade Prodrug Inc. Combination therapy with a vinca alkaloid n-oxide and an immune checkpoint inhibitor
US20250009731A1 (en) 2021-11-08 2025-01-09 Nurix Therapeutics, Inc. Toll-like receptor therapy combinations with cbl-b inhibitor compounds
US20250101438A1 (en) * 2022-01-21 2025-03-27 Trisalus Life Sciences, Inc. Methods of treating immune dysfunction in liver cancer with toll-like receptor agonists
WO2024186193A1 (ko) * 2023-03-08 2024-09-12 인제대학교 산학협력단 국소적 방사선 치료에서 전신성 항암 치료를 위한 조성물

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE356630T1 (de) * 1998-04-03 2007-04-15 Univ Iowa Res Found Verfahren und produkte zur stimulierung des immunsystems mittels immunotherapeutischer oligonukleotide und zytokine
EP1080225A4 (en) * 1998-05-21 2004-02-04 Isis Pharmaceuticals Inc COMPOSITIONS AND METHODS FOR THE PULMONAL ADMINISTRATION OF NUCLEIC ACIDS
KR100881923B1 (ko) 2000-12-27 2009-02-04 다이나박스 테크놀로지 코퍼레이션 면역자극 폴리뉴클레오티드 및 그것의 사용 방법
TW200303759A (en) * 2001-11-27 2003-09-16 Schering Corp Methods for treating cancer
WO2004004771A1 (ja) * 2002-07-03 2004-01-15 Ono Pharmaceutical Co., Ltd. 免疫賦活組成物
WO2004058179A2 (en) * 2002-12-23 2004-07-15 Dynavax Technologies Corporation Immunostimulatory sequence oligonucleotides and methods of using the same
US8158768B2 (en) 2002-12-23 2012-04-17 Dynavax Technologies Corporation Immunostimulatory sequence oligonucleotides and methods of using the same
CA2555390C (en) * 2004-02-19 2014-08-05 Coley Pharmaceutical Group, Inc. Immunostimulatory viral rna oligonucleotides
CN101134046B (zh) 2006-09-01 2011-10-05 中国医学科学院药物研究所 Tlr4和tlr9激动剂复方在抑制肿瘤转移中的应用
KR20110111517A (ko) * 2009-01-30 2011-10-11 이데라 파마슈티칼즈, 인코포레이티드 Ｔｌｒ9의 합성 효능제
AU2012257487A1 (en) * 2011-05-19 2014-01-16 Teva Pharmaceutical Industries Ltd. Method for treating non-small cell lung cancer
IL292510A (en) * 2013-11-05 2022-06-01 Cognate Bioservices Inc Combinations of checkpoint inhibitors and therapeutics to treat cancer
ES2752063T3 (es) * 2015-05-29 2020-04-02 Dynavax Tech Corp Administración intrapulmonar de agonistas polinucleotídicos del receptor de tipo toll 9 para el tratamiento del cáncer de pulmón
KR20180014010A (ko) * 2015-05-29 2018-02-07 머크 샤프 앤드 돔 코포레이션 암을 치료하기 위한 항-il-10 항체 및 cpg-c 유형 올리고뉴클레오티드의 조합
AU2017250348A1 (en) * 2016-04-15 2018-10-11 Dynavax Technologies Corporation Intratumoral administration of particles containing a Toll-like receptor 9 agonist and a tumor antigen for treating cancer

Also Published As

Publication number Publication date
EP3590518B1 (en) 2024-03-20
CN107708706A (zh) 2018-02-16
RU2017145940A (ru) 2019-07-02
MX381587B (es) 2025-03-12
US20190151345A1 (en) 2019-05-23
AU2016270782B2 (en) 2021-08-12
US20180264023A1 (en) 2018-09-20
KR20180021700A (ko) 2018-03-05
ES2752063T3 (es) 2020-04-02
EP3302502B1 (en) 2019-08-28
DK3302502T3 (da) 2019-10-28
JP2018521011A (ja) 2018-08-02
EP3590518A1 (en) 2020-01-08
AU2016270782A1 (en) 2017-12-07
JP6792294B2 (ja) 2020-11-25
KR102779525B1 (ko) 2025-03-12
NZ737488A (en) 2024-12-20
HK1251471A1 (zh) 2019-02-01
WO2016196062A1 (en) 2016-12-08
ES2987696T3 (es) 2024-11-15
EP3302502A1 (en) 2018-04-11
US20160346312A1 (en) 2016-12-01
IL255903B (en) 2021-09-30
IL255903A (en) 2018-01-31
US9993495B2 (en) 2018-06-12
US10369168B2 (en) 2019-08-06
CA2987237A1 (en) 2016-12-08
US10111899B2 (en) 2018-10-30
RU2017145940A3 (es) 2019-11-26

Similar Documents

Publication Publication Date Title
MX2017015294A (es) Administracion intrapulmonar de agonistas de polinucleotidos del receptor 9 tipo toll para el tratamiento contra el cancer de pulmon.
CO2020016619A2 (es) Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso
ECSP18038868A (es) Conjugados de anticuerpo que comprenden un agonista del receptor tipo toll
MX2023007841A (es) Metodos, composiciones y componentes relacionados con crispr-cpf1 para la inmunoterapia contra el cancer.
CL2017002637A1 (es) Compuestos nucleósidos 5'-sustituidos.
CL2018001512A1 (es) Anticuerpos anti-cd73 humanizados.
UY35643A (es) Nuevos compuestos útiles como nematicidas, sus composiciones y métodos de uso
MX2020005634A (es) Composiciones y metodos para mejorar los linfocitos infiltrantes de tumor para terapia celular adoptiva.
CL2018003473A1 (es) Nuevos derivados piperidinilo sustituidos con hetero(arilo), un proceso para su preparación y composiciones farmacéuticas que los contienen.
CL2018001230A1 (es) Tratamiento de osteoartritis
MX2021013520A (es) Antagonistas de union al eje pd-1 y taxanos para usarse en el tratamiento de cancer.
MX2016012446A (es) Derivados de quinoxalina utiles como amortiguadaores de receptor del factor de crecimiento de fibroblastos (fgfr) cinasa.
CL2018001722A1 (es) Nuevos anticuerpos anti-mfi2 y métodos de uso (divisional solicitud 201700506)
MX2021006804A (es) Antagonistas policiclicos del receptor 7/8 tipo toll (tlr7/8) y uso de los mismos en el tratamiento de trastornos inmunitarios.
MX373280B (es) Anticuerpos anti-egfrviii y usos de los mismos.
CL2018000786A1 (es) Nuevos derivados de pirrolo[2,3-d]pirimidina, un proceso para su preparación y composiciones farmacéuticas que los contienen.
BR112015019432A2 (pt) Compostos de tubulisina, métodos de produção e uso
MX2014011583A (es) Metodos y composiciones para el tratamiento de la familia de tumores del sarcoma de ewing.
MX2019015204A (es) Uso del anticuerpo anti-cd70 argx-110 para el tratamiento de leucemia mieloide aguda.
CL2016001151A1 (es) Derivados de purina 2,6-sustituidos y su uso en el tratamiento de trastorno proliferativos.
DOP2017000202A (es) Desacetoxitubulisina h y análogos de esta
BR112017018073A2 (pt) agentes de escoramento de poliolefina de ultra alto peso molecular
MX2018004664A (es) Antagonistas de ep4.
MX2018007818A (es) Anticuerpos dirigidos contra upk1b novedosos y metodos para su uso.
MX2017003365A (es) Tinturas dispersas altamente resistentes a la humedad y sus mezclas.